To all in-house counsel working in the pharmaceutical, medical device, biotech, and digital health industries: if you’re looking to complete a few final CLE hours before the end of 2025, we invite you to attend Reed Smith’s annual Virtual Life Sciences CLE Week, taking place from November 3 through November 7, 2025.

This week-long event will feature a series of timely and thought-provoking sessions focused on the legal and regulatory issues shaping the life sciences industry today. Several of your favorite bloggers will be speaking. Topics will include developments in artificial intelligence, evolving drug pricing frameworks, key ethical considerations, fraud and abuse enforcement trends, vaccine product liability developments, emerging product liability and toxic tort issues, transactional insights, and legal perspectives on women’s health.

Here are descriptions of the topics and the registration link.

The New EU Product Liability Directive | Presented by Lisa M. Baird, Daniel Kadar, Jamie L. Lanphear, Cynthia O’Donoghue, Oliver Rathje, and Wim Vandenberghe | This session unpacks the sweeping changes in the EU’s new Product Liability Directive and how they impact risk for life sciences and digital health companies operating in the EU.

Life Sciences Early-Stage Dealmaking | Presented by Nicole J. Aiken-Shaban, Michelle A. Mantine, Sarah Thompson Schick | A practical overview of early-stage life sciences deals trends and the critical diligence, regulatory, and antitrust considerations companies must navigate.

Navigating the Evolving Frontier of Women’s Health and Fertility Treatments | Presented by Sarah Cummings Stewart and Kristin B. Parker| Explore the shifting legal and regulatory landscape affecting women’s health and fertility treatments, with actionable strategies for compliance and risk management.

From Pharma to Produce: California’s Evolving Tort Terrain | Presented by Steven J. Boranian and Sarah B. Johansen | This California-focused legal update covers key tort developments impacting industries from pharmaceuticals to food, with implications for future litigation strategies.

AI and Life Sciences: A Collision Course | Presented by Tyler J. Thompson and Abigail Walker | Dive into how emerging U.S. AI regulations uniquely affect life sciences companies and what compliance measures should be taken now to prepare.

Recent Developments in Vaccine Product Liability Litigation | Presented by Jim Beck | Gain insight into the legal framework and current litigation trends surrounding vaccine liability, including the Vaccine Act, PREP Act, and COVID-19-related cases.

A World Without Government Pricing Programs | Presented by Joesph Metro | This session explores the legal, operational, and ethical implications for drug manufacturers considering alternatives to participation in federal pricing programs.

AI and Ethics: Navigating and Challenging Improper Use in Legal Proceedings | Presented by Jaclyn M. Setili Wood, Christian W. Castile and Charlotte Flynn| Learn how courts are responding to AI misuse in litigation and how legal teams can proactively address ethical and evidentiary challenges.

Hot Topics in Fraud and Abuse for Medical Device Manufacturers | Presented by Caitlin Chambers and Nancy Bonifant Halstead | An in-depth look at recent enforcement trends and compliance strategies to address key fraud and abuse risks facing medical device manufacturers.

Toxic Tort Litigation in the Life Sciences and Consumer Health Industry: Key Cases and Emerging Trends | Presented by Matthew D. Jacobson and Alexis A. Rochlin | A forward-looking analysis of the evolving toxic tort landscape, featuring notable cases and risk mitigation strategies for life sciences and consumer health companies.

Something New Under the Sun? Novel Preemption Topics | Presented by Lisa M. Baird and Heather A. Ritch Rocks | Explore emerging preemption issues for biosimilars and de novo devices, with expert perspectives on how courts may shape the future of product liability defenses.

CLE Information

“AI and Ethics: Navigating and Challenging Improper Use in Legal Proceedings” is presumptively approved for 1.0 CLE ethics credit in California, Connecticut, Illinois, New Jersey, New York, Pennsylvania, Texas, and West Virginia. Applications for CLE credit will be filed in Colorado, Delaware, Florida, Georgia, Ohio, and Virginia. Attendees who are licensed in other jurisdictions will receive a uniform certificate of attendance, but Reed Smith only provides credit for the states listed. Please allow 4-6 weeks after the program to receive a certificate of attendance.

Each remaining webinar is presumptively approved for 1.0 CLE credit in California, Connecticut, Illinois, New Jersey, New York, Pennsylvania, Texas and West Virginia. Applications for CLE credit will be filed in Colorado, Delaware, Florida, Georgia, Ohio, and Virginia. Attendees who are licensed in other jurisdictions will receive a uniform certificate of attendance but Reed Smith only provides credit for the states listed. Please allow 4-6 weeks after the program to receive a certificate of attendance.

CLE Questions? Contact Learning & Development CLE Attendance